Skip to main content
The Journal of Biological Chemistry logoLink to The Journal of Biological Chemistry
. 2025 Sep 1;301(10):110671. doi: 10.1016/j.jbc.2025.110671

Conformational dynamics of the bacterial E3 ligase SspH1

Cassandra R Kennedy 1, Diego Esposito 1, Jessica Huber 1, David House 2, Katrin Rittinger 1,∗
PMCID: PMC12506513  PMID: 40902981

Abstract

The SspH/IpaH family of novel E3 ligases are found in a number of Gram-negative bacteria and are used to target host enzymes for degradation to support pathogenesis. These E3 enzymes are autoinhibited in the absence of substrate, and different models for release of autoinhibition have been suggested. However, many of the molecular details of individual steps during the ubiquitin (Ub) transfer reaction remain unknown. Here, we present the crystal structure of Salmonella SspH1 and an analysis of the solution properties of SspH1 on its own and in complex with substrate and Ub. Our data show that SspH1 exists in a conformational equilibrium between open and closed states and that substrate binding only modulates the distribution of these states but does not induce major conformational changes. This suggests that additional mechanisms must exist to bring the substrates close to the active site to mediate transfer of Ub from the E3–Ub conjugate.

Keywords: E3 ubiquitin ligase, ubiquitination, structure–function, protein dynamic, virulence factor, enzyme mechanism


Gram-negative bacteria remain a huge disease burden globally. Shigella and nontyphoidal Salmonella together account for an estimated 660,000 human deaths worldwide each year (1). A key part of Salmonella and Shigella pathogenesis is the delivery of virulence proteins (effectors) into the host cell through a type 3 secretion system to interfere with host immune responses and support bacterial replication (2, 3). Effector proteins perform a range of cellular functions and often have enzymatic activities that include proteases, acetyltransferases, kinases, phosphatases, E3 ubiquitin (Ub) ligases, and deubiquitinases (2). Ubiquitination plays an important role in the regulation of eukaryotic cellular processes and is a key mechanism to target proteins for proteasomal degradation. It is mediated by a three-step enzymatic cascade including E1 activating, E2 conjugating, and E3 ligase enzymes (4). Intriguingly, bacteria do not have a canonical Ub system themselves but have evolved proteins that mimic and hijack the host Ub system to support their survival and proliferation (5, 6, 7). Many pathogenic bacteria contain E3 ligases, most of which structurally resemble their eukaryotic counterparts, yet some bacteria, including Salmonella and Shigella, have evolved a new class of E3 ligases, the novel E3 ligase (NEL) family, that have no structural homology to eukaryotic E3s in their catalytic domain but function via an active site cysteine, analogous to HECT or RBR E3 ligases (8, 9). These catalytic cysteine-containing E3 ligases transfer Ub onto the substrate in a two-step reaction: first, Ub is transferred from the E2–Ub conjugate to form an E3–Ub conjugate in a transthiolation reaction, and subsequently onto lysine residues in the substrate or Ub itself via an aminolysis reaction.

NELs are found in a number of Gram-negative bacteria, such as the mammalian pathogens Salmonella and Shigella and plant pathogens Ensifer fredii and Ralstonia solanacearum (10). They are composed of an N-terminal secretion motif, a leucine-rich repeat (LRR) domain, and a C-terminal NEL catalytic domain and are structurally conserved across the family. Crystal structures and mechanistic studies of NELs have provided insight into the activities of the two key functional domains: the LRR domain (9), which is responsible for substrate recognition, and the NEL domain (8), which can be divided into two subdomains: the C-terminal subdomain containing the E2–Ub binding domain (E2–UbBD) “thumb" and the N-terminal subdomain, which encompasses the catalytic E3 region containing the active site cysteine (11). A linker region joins the LRR and NEL domains together; however, the mechanistic role and importance of the flexibility of this linker remain poorly defined.

The Shigella NEL family members comprise IpaH proteins, with the best characterized members being IpaH9.8, IpaH1.4/2.5, and IpaH7.8, whose targets include GBP1 (12, 13, 14), Ste7 (15), NEMO (16), LUBAC (17), and gasdermin B (18). The Salmonella NEL subfamily includes SspH1, SspH2, and SlrP, which target PKN1 (19, 20), NOD1/SGT1 (21), and thioredoxin (Trx) (22), respectively. Upon ubiquitination, these host proteins are directed to proteasomal degradation, thereby suppressing the host immune and inflammatory response to bacterial infection.

The exact mechanism underlying the regulation of NEL E3 ligase activity has been the subject of many studies, and multiple, at times conflicting, mechanistic models for regulation have been put forward. The isolated NEL domain is constitutively active and forms free Ub chains, while ubiquitination activity is suppressed in the full-length (FL) proteins (8). Inhibition of NEL activity is important to prevent autoubiquitination and subsequent proteasomal degradation or formation of unanchored Ub chains, which could stimulate a host immune response (23, 24, 25, 26). Based on early crystal structures of NEL ligases, including IpaH3 (9), SspH2, (28), and IpaH9.8 (29), capturing two distinct “open” and “closed” conformations of the NEL proteins, it was suggested that autoinhibition might be due to steric blockage of the catalytic region by the LRR domain. In the “closed” conformation (SspH2, Protein Data Bank [PDB] code: 3G06), the LRR domain is oriented toward the NEL domain, thereby apparently occluding access to the catalytic cysteine until release of inhibition by substrate binding (27). In “open" conformations (IpaH3, PDB code: 3CVR; IpaH9,8, PDB code: 6LOL), the LRR domain is orientated away from the NEL domain, and these were assumed to represent active conformations. However, IpaH9.8 does not autoubiquitinate despite crystallizing in an “open” conformation, indicating that additional inhibitory mechanisms must exist. A recent study on IpaH9.8 has suggested that this may rely on two residues in the concave surface of its LRR that sense substrate binding and, in response induce a conformational change to release a hydrophobic cluster that mediates autoinhibition. This mechanism requires an amplifier loop in the LRR domain, which, however, is not present in all family members, raising the question of how other NELs are autoinhibited (29). Independently, an elegant biochemical study using mutants of catalytic acid and base residues showed that lack of activity is not because of restricted access to the catalytic cysteine in the absence of substrate binding but that an E3–Ub intermediate is formed, which, however, undergoes rapid nonproductive Ub turnover in the absence of substrate (30). How substrate binding prevents such nonproductive turnover remains unknown.

If any of these described regulatory mechanisms apply across the entire NEL family is currently unclear, nor have the intermediate steps in the Ub transfer reaction been captured structurally. The first step in substrate ubiquitination, the initial transfer of Ub from E2 to the NEL, has been described to rely on significant intradomain flexibility between the catalytic E3 region and the E2–UbBD thumb (11). In contrast, the structural determinants that mediate the switch from unproductive hydrolysis of the E3–Ub intermediate to Ub transfer onto substrate lysine residues is not understood. Similarly, the effect of substrate binding on the conformational flexibility of the LRR and NEL domains with respect to one another has not been studied.

To address these questions, we present a comparison of catalytic activities of NEL proteins across the Shigella and Salmonella subfamilies, highlighting similarities and differences between family members. To better understand the molecular mechanism of SspH1, we combine the structural characterization of SspH1 by crystallography with small-angle X-ray scattering (SAXS) and NMR analysis to interrogate the solution-state structure and conformational flexibility of SspH1 when bound to its substrate PKN1 and to Ub. Our data indicate that the open and closed forms of SspH1 are in a conformational equilibrium and that substrate binding modulates the distribution between closed and open states but does not induce major conformational changes. Similarly, substrate binding has only a minor effect on the flexibility of Ub in the E3–Ub conjugate, suggesting that additional as yet unknown mechanisms must exist to bring the LRR-bound substrate close to the Ub thioester intermediate and initiate Ub transfer.

Results

Comparison of IpaH1.4, IpaH9.8, SspH1, and SspH2 catalytic activities

NELs are highly homologous in their catalytic NEL domain, and many residues previously identified as important for catalytic activity, including residues responsible for E2–Ub binding as well as catalytic acid and catalytic base residues, are conserved across the family. The main differences between NEL family members are in the LRR domains, which mediate substrate recognition but may also affect Ub transfer as suggested for the amplifier loop in IpaH9.8. To investigate if the mechanism of Ub transfer of NELs is conserved across the family, we compared catalytic activities across four family members: two Shigella proteins, IpaH1.4 and IpaH9.8, and two Salmonella proteins, SspH1 and SspH2, as these have well-established substrates. A sequence alignment of these family members is shown in Figure S1A (31), highlighting not only the conservation of key catalytic residues but also differences such as the lack of the IpaH9.8 amplifier loop in SspH1 and SspH2. The LRR domain of SspH2 is longer compared with the other three proteins, corresponding to 12 LRR repeats compared with eight repeats for IpaH9.8 and 1.4 (28, 29). Structural models generated by AlphaFold2 (AF2) predict an additional globular N-terminal domain in SspH1 and SspH2, which is structurally conserved across the two proteins (Fig. S1B) (32, 33, 34), and found in other bacterial effectors such as SifA, though its function in E3 ligase activity has not been investigated thus far.

To interrogate the mechanisms of Ub transfer across the Shigella IpaH and Salmonella SspH proteins, we purified three constructs for each of IpaH1.4, IpaH9.8, SspH1, and SspH2: the FL protein; the NEL domain; and the FL protein minus the N-terminal secretion signal or globular domain in SspH1 and SspH2 (ΔN) (Fig. 1). First, we confirmed substrate ubiquitination activity of IpaH1.4, IpaH9.8, and SspH1 with their respective substrates LUBAC, GBP1, and PKN1 HR1b domain for the ΔN (Fig. 1) and FL constructs (Fig. S2A). Substrate ubiquitination by SspH2 could not be investigated because of difficulties with producing a sufficiently pure SGT1–NOD1 substrate complex. For each construct of each protein, we performed a further three types of assays to assess activity: first, we performed in vitro ubiquitination assays, where overall E3 ligase activity is monitored through autoubiquitination or formation of free Ub chains. Next, we carried out E2–Ub complex discharge assays using fluorescently labeled Ub to isolate the E2–Ub and E3–Ub formation steps of the Ub cascade. If a stable E3–Ub intermediate is formed, this can be observed on nonreducing SDS gels. Finally, we performed Ub-loading assays with a covalent Ub probe (ubiquitin vinyl sulfone [UbVS]) to assess accessibility of the E3 catalytic cysteine.

Figure 1.

Figure 1

ΔN NEL activity assays. A, diagram of constructs of NEL bacterial E3 ligases IpaH1.4, IpaH9.8, SspH1, and SspH2; B, substrate ubiquitination assay with ΔN constructs of IpaH1.4 (substrate LUBAC), IpaH9.8 (substrate GBP1), and SspH1 (substrate HR1b PKN1). Performed with 0.1 μM UBA1 (E1), 2 μM UbcH5A (E2), 1.0 μM ΔN NEL (E3), 20 μM ubiquitin (Ub), and 10 mM ATP at room temperature for 30 min with either 1 μM (LUBAC, GBP1) or 2 μM (HR1b PKN1) substrate. C, autubiquitination assay with ΔN constructs of IpaH1.4, IpaH9.8, SspH1, and SspH2. Performed with 0.1 μM UBA1 (E1), 2 μM UbcH5A (E2), 1 μM ΔN NEL (E3), 20 μM Ub, and 10 mM ATP at room temperature for 30 min. D, E2–Ub discharge assay with ΔN IpaH1.4 and IpaH9.8. Performed with 1 μM UbcH5A–Ub-cy3 (E2–Ubcy3), 5 nM NEL (E3) at room temperature for 0 to 30 min. E, E2–Ub discharge assay with ΔN SspH1 and SspH2. Performed with 1 μM UbcH5A–Ub-cy3 (E2–Ubcy3), 50 nM NEL (E3) at room temperature for 0 to 30 min. Assays for full-length constructs are in Figure S2. F, ubiquitin-loading assay with ΔN constructs of IpaH1.4, IpaH9.8, SspH1, and SspH2. Performed with 20 μM UbVS, 5 μM ΔN NEL (E3) at room temperature for 2 h. Samples in B, C, and F were resolved by SDS-PAGE and stained with Coomassie. NEL, novel E3 ligase.

As expected, we observe some similarities in activities across the four Shigella and Salmonella NELs. In substrate ubiquitination assays, we observed equal substrate ubiquitination with both ΔN and FL proteins, indicating that the N-terminal globular domain present in SspH1/2 has no effect on catalytic activity (Figs. 1, Fig. S2A and S3B). In contrast, in the absence of substrate, no autoubiquitination or free chain formation activity was observed with ΔN and FL proteins (Figs. 1 and S2B). In E2–Ub discharge assays, FL and ΔN constructs discharge Ub from UbcH5A–Ub (Figs. 1, Fig. S2C and S3E), indicating that their catalytic cysteine is accessible but no stable E3–Ub thioester intermediate is formed. This is in agreement with the labeling observed with UbVS in Ub-loading assays (Figs. 1, S2D). All activities observed are dependent on the active site cysteine and specific substrate (Fig. 2). The isolated NEL domains alone did not autoubiquitinate; however, free Ub chains were synthesized, indicating that removal of the LRR domain released autoinhibition (Figs. 2, S3D). Similarly, in E2–Ub discharge assays with isolated NEL domains, some free di-Ub was synthesized (Fig. S2B), and all constructs were labeled by UbVS (Fig. 2). Interestingly, the E3–Ub thioester intermediate was sufficiently stable in these discharge assays that it could be observed at early time points with IpaH1.4, IpaH9.8, and SspH1.

Figure 2.

Figure 2

NEL domain activity assays. A, autoubiquitination assay with NEL domains of IpaH1.4, IpaH9.8, SspH1, and SspH2. Performed with 0.1 μM UBA1 (E1), 2 μM UbcH5A (E2), 1 μM NEL domains (E3), 20 μM ubiquitin (Ub), and 10 mM ATP at room temperature for 30 min. B, E2–Ub discharge assay with FL constructs of IpaH1.4, IpaH9.8, SspH1, and SspH2. Performed with 1 μM UbcH5A–Ub-cy3 (E2–Ubcy3), 0.2 μM NEL domain (E3) at room temperature for 0 to 30 min. C, ubiquitin-loading assay with NEL domains of IpaH1.4, IpaH9.8, SspH1, and SspH2. Performed with 20 μM UbVS, 5 μM NEL domain (E3) at room temperature for 2 h. FL, full length; NEL, novel E3 ligase; UbVS, ubiquitin vinyl sulfone.

However, we also observed differences between the activities of these proteins. Labeling with UbVS was different between the four NEL family members: both FL and ΔN constructs of IpaH9.8 and IpaH1.4 were approximately 50% labeled after 2 h, whereas SspH2 was almost completely labeled, in contrast to SspH1, which showed the lowest level of labeling (Figs. 1, S2D). With the NEL domains alone, labeling was more similar across the family (Fig. 2), though SspH1 still showed the lowest degree of labeling. In NEL domain–only ubiquitination assays, we observed a similar propensity to form free Ub chains with IpaH1.4 and IpaH9.8, whereas SspH1 and SspH2 appeared less active (Fig. 2).

Similarly, time-course E2–Ub discharge assays with ΔN constructs highlighted that IpaH1.4 and IpaH9.8 were much more efficient at discharging Ub than SspH1 or SspH2 (Fig. 1). To observe complete Ub discharge within the same time frame, a 10-fold higher concentration of SspH proteins was required when compared with the IpaH proteins. This corroborates previous work by Keszei and Sicheri (30), where longer assay time points were used to study SspH1 activity compared with IpaH9.8. For E2–Ub discharge assays with isolated NEL domains, we observed similar rates of free di-Ub synthesis with IpaH1.4 and IpaH9.8, whereas SspH2 was significantly less efficient compared with the other three proteins (Fig. 2). The reason for this difference in discharge efficiency of the isolated NEL domain of SspH2 compared with the FL protein is currently unclear, and we can only speculate that the nucleophilicity of the active site cysteine is reduced in the isolated NEL domain.

We found it intriguing that SspH1 is the apparently least accessible of the NELs tested to Ub loading with UbVS (Fig. 1) and has a lower turnover in discharge assays compared with IpaH proteins (Figs. 1, Fig. S2B) but is the most active in substrate ubiquitination assays (Fig. 1). Therefore, we tested whether the presence of PKN1 HR1b substrate might alter the dynamics of SspH1 and therefore the accessibility of the catalytic cysteine. However, we observed that PKN1 had no effect on SspH1 loading with UbVS Ub (Fig. S4A). This is complementary to and consistent with E2–Ub discharge assays performed by Keszei and Sicheri (30) where the addition of PKN1 HR1b to SspH1 had no impact on E2–Ub discharge rate, indicating that substrate binding does not significantly alter access to the SspH1 active site.

ΔNSspH1 crystal structure

To better understand the mechanism of SspH1 and the apparent differences in activity, we solved the crystal structure of a construct containing the LRR and NEL domains but lacking the first 160 residues, ΔNSspH1 (now referred to as SspH1). The structure was refined at 2.9 Å resolution with one copy in the asymmetric unit and a P622 space group. Details of data collection and statistics are reported in Table S1.

The structure is elongated with the LRR (residues 161–393) domain extending away from the NEL domain (residues 405–622), which contains the catalytic cysteine (C492) and the α-helices of the E2–UbBD (residues 623–697) (Fig. 3). It is similar to IpaH9.8 and IpaH3 in an “open" conformation, with the position of the E2–UbBD relative to the catalytic loop in an analogous position to other bacterial E3 ligase structures (Fig. 3). The E2–UbBD of SspH1 consists of two long antiparallel α-helices and a small C-terminal helical segment, as also seen in SspH2 (Figs. 3 and S1A). In contrast, IpaH9.8, IpaH1.4, and SlrP have a notable kink in one of the two long antiparallel α-helices (Fig. 3). In agreement with our sequence alignment (Fig. S1A), SspH1 lacks the amplifier loop in LRR6 of the IpaH9.8 LRR domain, which was shown to be important for GBP1 substrate sensing (29). SspH2 also lacks an amplifier loop, whereas IpaH3 is missing electron density for eight amino acids in the corresponding LRR, and SlrP has an extended loop in the next LRR domain (9, 28). Whether these loops act as signaling amplifiers upon substrate binding is unknown.

Figure 3.

Figure 3

Crystal structure of ΔNSspH1. A, overall structure from side and top view. The cysteine residue side chain in the catalytic loop is shown as spheres; B, overlay of ΔN NEL structures aligned to the NEL domain showing SspH1, SlrP (PDB code: 3PUF), IpaH9.8 (PDB code: 6LOL), and IpaH3 (PDB code: 3CVR) in the “open” conformation, and SspH2 (PDB code: 3G06) in the “closed” conformation; C, aligned E2–UbBD thumbs for SSpH1 and SspH2, and SlrP, IpaH9.8, and IpaH1.4 (PDB code: 3CKD). NEL, novel E3 ligase; PDB, Protein Data Bank.

In our SspH1 structure, 60 N-terminal residues, those in the LRR–NEL linker (394–404) and the loop containing the catalytic C492, have a higher B-factor compared with other residues, suggesting more flexibility in these regions. A highly dynamic LRR–NEL linker and catalytic loop might be an important mechanistic feature in bacterial E3 ligases, as high B-factors or lack of electron density are also observed for these regions in other available NEL structures that contain both LRR and NEL catalytic domains: ΔN SspH2, IpaH3, and IpaH9.8 do not have electron density for the LRR–NEL linker, whereas IpaH9.8 is also missing density for the catalytic loop (9, 29). SlrP is currently the only available structure of an LRR–NEL construct that has its substrate Trx bound. The complex crystallized as a heterotetramer, with the two SlrP molecules in an open, head-to-tail arrangement that are bridged by two molecules of Trx-1, though it is not known if self-association is required for substrate ubiquitination by SlrP. In this structure, there is a well-defined density for the loop linking the LRR and NEL domains, which makes contact with Trx-1 (35).

We observed a symmetry-related molecule in our structure of SspH1, where the E2–UbBD of one molecule sits on the top of the LRR domain, close to its substrate binding interface (Fig. S5A). To determine if this was a biologically relevant interaction or an artifact of crystal packing, we performed size-exclusion chromatography–multiangle laser light scattering (SEC–MALLS) measurements with FL SspH1 and ΔNSspH1. We confirmed that, in the range of concentrations explored, both are monomeric in solution (Fig. S5, B and C) and form a 1:1 complex with the substrate PKN1 (Fig. S5, D and E), in agreement with a previous report (11). This is in contrast to SlrP, which has been shown to exist in a monomer–dimer equilibrium (35).

We next interrogated the importance of residues in SspH1 that make contacts between the LRR and NEL domains to better understand the interplay between these two domains and their role in autoinhibition. R351, which is conserved in SspH1/2 and SlrP but not IpaH proteins, forms key interactions with E493 and D552, whereas R375, which is an Arg or a His across the NEL family (Fig. S1), points toward an acidic pocket formed by residues surrounding the catalytic acid and base (Figs. 4, Fig. S6A) (30). However, we observed no significant difference between mutants R351A, R375A, R351A R375A, and WT SspH1 activity in either autoubiquitination or PKN1 ubiquitination assays (Fig. 4), indicating that these residues do not regulate autoinhibition. In addition, hydrophobic interactions with L550 at its center further contribute to the LRR–NEL interface (Fig. S6A). This observation supports previous mutational analysis of L550, which showed that L550S partially released autoinhibition but had no apparent effect on substrate ubiquitination (27, 36). Interestingly, the L550D mutation changed the pattern of substrate ubiquitination, suggesting that this position affects the conformational changes required to bring the substrate close to the E3–Ub thioester (Fig. S6B).

Figure 4.

Figure 4

Interface between the LRR and NEL domains. A, interface between the LRR domain in green and the NEL domain in blue highlighting the interactions made between R351 (LRR) and E493 and D522 (NEL). The side chain of the catalytic cysteine is shown. B, top, autoubiquitination assay with ΔNSspH1 mutants R351A, R375A, R351A, and R375A. Performed with 0.1 μM UBA1 (E1), 2 μM UbcH5A (E2), 1.0 μM SspH1 (E3), 20 μM ubiquitin, and 10 mM ATP at room temperature for 0 to 30 min. Bottom, substrate ubiquitination assay with ΔNSspH1 mutants R351A, R375A, R351A, and R375A. Performed with 0.1 μM UBA1 (E1), 2 μM UbcH5A (E2), 1.0 μM SspH1 (E3), 2 μM HR1b PKN1, 20 μM ubiquitin, and 10 mM ATP at room temperature for 0 to 30 min. LRR, leucine-rich repeat; NEL, novel E3 ligase.

At present, the SlrP–Trx-1 complex is the only available structure of a near FL NEL bound to its substrate. However, the tetrameric nature of this complex makes it difficult to draw general conclusions about the mechanism of substrate ubiquitination, given that other NEL family members are assumed to transfer Ub in a 1:1 NEL–substrate complex. Furthermore, no structure of apo SlrP is available to assess conformational changes induced upon substrate binding. Instead, near FL IpaH9.8 has been structurally characterized in the apo state and the isolated LRR domain bound to its substrate GBP1, providing the first insight into the effect of substrate engagement (29). Comparison of these two structures allowed identification of structural changes induced in the LRR upon substrate binding, especially a rotation of the LRR–C terminus toward the convex side of the LRR, which destabilizes a hydrophobic cluster in the C terminus of the LRR that engages F395 (equivalent to L550 in SspH1) from the NEL, thereby enabling release of the NEL domain and autoinhibition. The structure of SspH1 presented here now allows us to carry out the same comparison using the previously published structures of the SspH1 LRR in its apo form and in complex with its substrate PKN1 HR1b (27). Interestingly, an overlap of the PKN1-bound LRR with SspH1 revealed that the changes induced upon substrate binding are much smaller than those observed in IpaH9.8 with an RMSD of 0.685 Å (Fig. S6), without any significant effect on the hydrophobic environment of L550. This suggests that substrate binding to SspH1 alone might not be sufficient to induce the conformational changes required to release autoinhibition.

Solution properties of FL and ΔNSspH1 and substrate-bound complexes

The observation that LRR and NEL domains adopt different orientations with respect to one another in crystal structures of apo NEL proteins indicates the presence of significant interdomain flexibility; however, little is known about substrate binding that affects this conformational flexibility. To investigate the solution properties of SspH1, we recorded SAXS data on FL and ΔNSspH1 constructs in the presence and absence of PKN1 (Fig. 5, Fig. S7). Details of data collection and analysis are reported in Table S2.

Figure 5.

Figure 5

Small-angle X-ray scattering (SAXS) analysis. Intensities profiles, normalized pair distance distribution P(R), and Kratky plot of ΔNSspH1 (A) and full-length SspH1 (B) in the absence and presence of PKN1. The dotted lines in the Kratky plot are drawn at qRg = √3 and (qRg)2I(q)/I(0) = 1.104. Folded and globular proteins have a maximum where the two lines intersect (50). C, LRR–NEL intradomain angles and distance distribution for the structural ensembles calculated by Xplor-NIH that represent the experimental X-ray scattering intensities (χ2 ≤ 1.5). D, the three-conformer structural ensemble that best agrees with the experimental SAXS data (lowest χ2). LRR, leucine-rich repeat; NEL, novel E3 ligase.

We observed a 75 Å decrease in the maximum dimension (Dmax) and a 14 Å reduction in the radius of gyration (Rg) for ΔNSspH1 compared with the FL protein, indicating a large contraction in the protein volume following the deletion of the small N-terminal domain. Interestingly, the change in molecular dimensions is not associated with a change in the respective radii of cross-section (Rc), suggesting that the overall structures maintain elongated shapes (Dmax >> Rg) of similar widths. Rather surprisingly, the Guinier analysis of ΔNSspH1 and FL protein scattering data reveals similar radii of gyration for both proteins in isolation and bound to the HR1b domain of PKN1 (Fig. S7A). A 10 Å increase in the maximum dimension of the normalized P(R) distributions is observed for both constructs following substrate recruitment, suggesting that only small molecular rearrangements occur upon PKN1 binding. In both cases, the molecular weights calculated from the SAXS data are those expected from the primary sequences, suggesting that the proteins in their apo forms and in complex with PKN1 are monomeric in solution with a 1:1 stoichiometry, as reported previously and in agreement with our SEC–MALLS analysis (Fig. S5) (11).

We assessed the flexibility of the protein constructs under investigation using dimensionless Kratky plots (Fig. 5). The broad-bell shape with a maximum shifted toward higher q∗Rg values, especially apparent in FL SspH1, together with the long tails in the P(r) distributions, confirms that SspH1 populates elongated conformations. Moreover, the uptrend of the Kratky profile at higher q∗Rg indicates the presence of overall conformational flexibility, which is unaffected by the presence of the substrate. Fitting the solution scattering data using either our ΔNSspH1 crystal structure coordinates or an AlphaFold3 (AF3) model, both of which are characterized by distinct orientations of the LRR and E2–UbBD relative to the catalytic E3 domain, yields large χ2 values in both cases. This indicates that neither structure accurately represents the solution conformation of SspH1, most likely because of its dynamic features. To explore the conformational space available to ΔNSspH1, we modeled solution structure ensembles based on the experimental X-ray scattering data using an Xplor-NIH–implemented protocol (37). Ensembles were chosen based on the agreement with the experimental data (χ2 ≤ 1.5) and visualized in a plot reporting the angles between the centers of mass of the E2–UbBD, E3, and LRR domains as a function of the distances between the E2–UbBD and LRR centers. Relative positions of the same domains in our ΔNSspH1 crystal structure, as well as the available structures of ΔNSspH2, IpaH3, and IpaH9.8, are also reported. ΔNSspH1 ensemble conformers possess significant interdomain flexibility, implying that the protein can adopt both extended (open) and more compact (closed) conformations (Fig. 5). Structure envelope maximum dimensions (Fig. S7C) and radii of gyration (Fig. S7D) for the crystal structures of ΔNSspH1, ΔNSspH2, ΔNIpaH9.8, and ΔNIpaH3 all fall within overall ensemble distributions for these parameters. Notably, the ensemble best agreeing with the experimental scattering data (lowest χ2 value) comprises two extended structures and a closed conformation, wherein the substrate binding interface on the LRR domain is oriented toward the catalytic loop (Fig. 5).

In conclusion, our SAXS data reveal that SspH1 exhibits significant interdomain flexibility suggesting that available crystal structures likely represent specific conformational snapshots within a continuous structural landscape. While PKN1 binding does not fundamentally alter SspH1 overall flexibility, we observed a subtle shift in the Kratky profile maximum toward smaller q∗Rg for both the FL protein and ΔNSspH1 upon PKN1 binding (Fig 5). This suggests that PKN1 binding might modulate the distribution of SspH1 closed and open conformations, resulting in a small increase in globularity of the average solution structure of the complex compared with the apo states.

Dynamic properties of the SspH1–Ub conjugate

We sought to better understand the structural flexibility of Ub when loaded to SspH1 alone (SspH1–Ub) and in complex with PKN1. Our SAXS analysis indicated subtle changes in SspH1 conformation upon PKN1 binding. Given the low efficiency of UbVS labeling (Fig. 1), which we used to form a stable SspH1–Ub covalent conjugate, we employed NMR to study how E3 conjugation affects Ub dynamic behavior.

We first examined the noncovalent interaction of SspH1 with 15N-labeled Ub by monitoring the effect of SspH1 addition on the backbone amide resonances in the 1H–15N heteronuclear single quantum coherence (HSQC) spectrum of a 15N-labeled Ub sample (Fig. 6). Fast exchange in a subset of Ub backbone amide resonances was observed upon SspH1 addition (Fig. 6). The perturbed resonances are located at the Ub N- and C-terminal residues and amide protons around the Ub I44 hydrophobic patch (Fig. 6). Incremental line broadening was also observed for the perturbed resonances in the Ub spectrum, likely because of the increase in molecular size and longer correlation times upon interaction with SspH1. Next, we probed the interaction of the Ub with the individual SspH1 domains. Chemical shift perturbations (CSPs) were still visible, but fewer resonances were affected in the 1H–15N HSQC spectrum when the isolated NEL domain was added to 15N-labeled Ub compared with SspH1 (Fig. 6). The differences in the two interfaces are located mainly in the Ub C-terminal tail (Fig. 6). Resonance line broadening is also less pronounced in the titration of 15N–Ub with the NEL alone compared with SspH1 (Fig. 6). These observations point to a direct participation of the LRR domain in the SspH1–Ub interaction. In fact, a titration of Ub with SspH1 featuring a largely flexible and independent LRR domain would have shown the same profile of CSPs and line broadening observed for the titration of Ub with the isolate NEL domain. Addition of the LRR domain alone to 15N-labeled Ub led to a largely unperturbed 1H–15N HSQC spectrum, with some crosspeaks experiencing small CSPs and associated resonance broadening (Fig. 6). Similarly to the interaction with the NEL, residue-specific line-broadening analysis revealed that residues primarily located in the N- and C-terminal regions of Ub experience larger effects upon interaction with the LRR (Fig. 6). Although the LRR–Ub interaction is relatively weak, it does not engage the I44 hydrophobic patch, as observed in the NEL interaction. Instead, the line-broadening predominantly affects residues located further downstream, specifically L50, L56, and K63, indicating that the two domains engage slightly distinct surfaces on the Ub molecule.

Figure 6.

Figure 6

NMR analysis of the SspH1–ubiquitin (Ub) interaction. Details of the titration of 15N-labeled Ub titrated with ΔN SspH1 (A) SspH1 NEL domain (B), and SspH1 LRR domain (C). Spectra at different ligand concentrations are plotted at the same contour level. Chemical shift perturbations (CSPs) versus residue number in the NMR spectrum of 15N-labeled Ub in the presence of (D) ΔN SspH1 or (E) NEL domain with CSPs mapped onto Ub structure (G and H). Ub 1H–15N HSQC line broadening versus residue number for the titration with the LRR domain with the rate of broadening mapped onto Ub structure (F and I). HSQC, heteronuclear single quantum coherence; LRR, leucine-rich repeat; NEL, novel E3 ligase.

To try and rationalize these observations, we used AF3 to model the structure of ΔNSspH1 bound to Ub (Fig. S8A) (38). In the predicted SspH1–Ub complex, the SspH1–Ub interface aligns with the cluster of Ub residues experiencing CSPs observed in the NMR titration experiments with the ΔNSspH1 and NEL domain. To investigate whether SspH1 uses the predicted surface to interact with Ub, we mutated a glutamate residue (E487) in SspH1 that appears to serve as a linchpin for binding, being packed between the side chains of R72 and R42 of Ub (Fig. S8A). We hypothesized that, if this was the correct E3–Ub binding mode, the E487 mutation to alanine would weaken Ub binding, whereas the mutation to arginine would completely abrogate it. Whilst there was no difference in the effect on the backbone amide resonances in the 1H–15N HSQC spectrum of an 15N-labeled Ub sample upon addition of either WT or E487R SspH1 (Fig. S8B), we observed disrupted discharge and substrate ubiquitination activity for the E487A mutant and its ablation for the E487R mutant (Fig. S8, C and D). This indicates that whilst E487 has a role in SspH1 activity, the AF3-predicted interface between the Ub and SspH1 is likely not the primary function of this residue. Instead, E487 interacts with H498, which has previously been shown to be important for the transfer of Ub from E3–Ub to the substrate (Fig S8E) (11). Interestingly, these two residues are located on the helices on either side of the catalytic loop containing C492, suggesting that their interaction may stabilize its position to support catalysis.

Next, we investigated the dynamic behavior of Ub in the SspH1–Ub conjugate and how it is altered by PKN1 binding. We recorded 1H–15N HSQC spectra of SspH1 preloaded with 15N-labeled Ub UbVS probe and monitored the effect on Ub resonances in the SspH1–Ub conjugate when PKN1 is added (Fig. 7). While the charging of SspH1 with the 15N-Ub probe is inefficient, this approach is suitable for NMR experiments, as only the charged 15N-labeled Ub in the SspH1–Ub conjugate is visible in the spectra. We first confirmed that the 1H–15N HSQC spectrum of the free 15N-Ub UbVS probe remains largely indistinguishable from that of the WT protein, except for a few C-terminal residues, implying that the addition of the vinyl sulfone warhead does not induce structural changes in Ub. Upon conjugation to the SspH1 catalytic cysteine, most backbone resonances in the 15N-labeled Ub 1H–15N HSQC spectrum probe decrease in intensity, with a subset experiencing a stronger line broadening effect (Fig. 7). The remaining visible crosspeaks (backbone and side-chain amide resonances) in the 1H–15N-HSQC spectrum show no change in their chemical shifts. A possible interpretation of this observation is that in the SspH1–Ub conjugate, the Ub exists in fast exchange between two states: a predominant, flexibly tethered state, visible by NMR, and a less abundant, locked state, invisible in the 1H–15N HSQC Ub spectrum because of its high molecular weight (∼70 kDa). This equilibrium would explain the observed pattern of line broadening and the persistence of some visible peaks. It suggests that while Ub is not permanently locked in a rigid conformation with SspH1, it does transiently become locked in a larger complex, possibly involving interactions with both the NEL and LRR domains. Upon addition of PKN1 substrate to the SspH1–Ub conjugate, there is an overall increase in the Ub crosspeak intensity and a subset of Ub resonances, which were previously invisible or weak, either reappear or increase in intensity (Fig. 7). This indicates a shift in the fast exchange equilibrium between the locked and flexible Ub states toward a more dynamic conformation. This shift may result from the loss of one or more interaction surfaces between Ub and SspH1 upon PKN1 binding. Intriguingly, the resonances that showed increased intensity cluster into defined patches on the Ub molecule, encompassing the N-terminal region, the I44 hydrophobic surface, and downstream residues up to Y59. These regions overlap with the interfaces identified in our NMR experiments with free Ub interacting with the NEL and LRR domains of SspH1, suggesting that substrate binding may weaken these interactions (Fig. 6).

Figure 7.

Figure 7

NMR of conjugated15N-labeled ubiquitin (Ub). Spectra of 15N-Ub tethered to ΔNSspH1 C492 in the absence (A) and presence (B) of PKN1. Residues in the Ub 1H–15N HSQC spectrum reappear upon addition of the substrate. The reappearing residues are plotted on the Ub structure in (C). HSQC, heteronuclear single quantum coherence.

Taken together, our NMR experiments show that Ub noncovalently interacts with both the NEL and LRR domains of SspH1. Our results with tethered Ub, which mimics the activated E3–Ub intermediate, suggest that, in the SspH1–Ub conjugate, the LRR domain restricts Ub dynamic behavior and substrate binding impacts Ub flexibility in the SspH1–Ub/PKN1 complex.

Discussion

Bacterial NEL E3 ligases have an important role in Salmonella and Shigella evasion of host cell immune responses during infection; however, the exact molecular mechanism of Ub transfer and regulation of activity remains unclear. In this study, we performed a cross-species comparison of NEL catalytic activity. We showed that active site cysteines of FL IpaH and SspH proteins are readily accessible for Ub loading but are immediately discharged, confirming that autoinhibition is not because of steric blockage of the catalytic cysteine and supporting the model that water is the favored nucleophile for Ub discharge in the absence of substrate (30). This activity is advantageous to the bacteria, since it prevents autoubiquitination and proteasomal degradation of the NELs themselves and unanchored Ub chain formation, which could trigger the host cell innate immune response. However, we also identified differences in activity between Salmonella and Shigella NELs. To better understand these differences, we solved the crystal structure of an SspH1 construct containing both LRR and NEL domains. When compared with previously published structures for SspH2, IpaH9.8, and IpaH3, SspH1 is most similar in orientation to IpaH9.8 and IpaH3, with an “open” conformation.

Previous work had shown that NEL family members rely on significant flexibility within the NEL domain to recruit Ub (11). While available crystal structures of NEL proteins and substrate complexes provide snapshots of specific states, little is known about how Ub loading affects conformational dynamics of the ligase, how substrate binding affects the overall protein dynamics of NELs, and how Ub is passed onto the substrate. Here, we have characterized the solution-state behavior of SspH1 by SAXS and showed that it exists in a conformational continuum, which include the orientations captured in the crystal structures of SspH2, IpaH9.8, and IpaH3. Furthermore, our SAXS analysis shows that apo SspH1 has a significant level of flexibility around the hinge between the LRR and NEL domains, which is not substantially affected by substrate binding, though it shifts the equilibrium toward more globular conformations of SspH1. NMR experiments with free 15N-labeled Ub and a 15N-labeled Ub probe loaded onto the catalytic cysteine of SspH1 enabled us to study the environment of Ub in the presence of SspH1 and PKN1. These experiments suggest that Ub is partially restrained when noncovalently or covalently bound to SspH1, forming transient interactions with the NEL domain and possibly weaker interactions with the LRR domain. The interactions with the LRR domain are relieved upon PKN1 binding.

The crystal structure of the SspH1 construct containing both the LRR and NEL domains allowed comparison with the previously reported substrate-bound LRR domain structure, to identify potential changes induced upon substrate binding, as previously described for IpaH9.8. Interestingly, no significant structural changes are induced by the substrate, indicating that the mechanism of release of autoinhibition suggested for IpaH9.8 must be protein specific and not generally applicable to this protein family. Instead, we identified E487 in the NEL as important for activity. This residue interacts with H498 from the adjacent helix, which has previously been reported to be important for Ub transfer from E3 onto the substrate and we speculate that interaction between these two residues might be important for stabilizing the catalytic loop.

Taken together with previously published studies, the work presented here suggests that substrate binding to the LRR domain of NEL proteins is not sufficient to induce the conformational changes required to bring the substrate close to the E3–Ub thioester intermediate to enable Ub transfer. At present, it is unknown what additional events are necessary to promote formation of a Ub transfer competent conformation of a substrate–NEL–Ub complex, and further studies are required to trap members of this enigmatic E3 ligase family in their active state.

Experimental procedures

Protein expression and purification

All proteins were expressed in pET49b vectors containing a 3C cleavage site and His-tag in BL21 Gold Escherichia coli in LB media. Cells were grown at 37 °C until an absorbance at 600 nm reached 0.6 to 0.8, and protein expression induced with 0.5 mM IPTG overnight at 20 °C. Cells were lysed by sonication in 50 mM Hepes (pH 7.5), 150 mM NaCl, 20 mM imidazole, 0.5 mM Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) in the presence of protease inhibitor. Proteins were purified on nickel–nitrilotriacetic acid resin (Thermo Scientific; #88222), followed by elution and treatment with 3C protease overnight. Proteins were then purified by gel filtration into 50 mM Hepes (pH 7.5), 150 mM NaCl, and 0.5 mM TCEP. The following constructs were used in activity assays:

FL constructs: IpaH1.4 1 to 575, IpaH9.8 1 to 545, SspH1 1 to 700, SspH2 1 to 788.

ΔN constructs: IpaH1.4 31 to 575, IpaH9.8 21 to 545, IpaH9.8 21 to 545 C337A, SspH1 161 to 700, SspH1 161 to 700 C492A, SspH2 166 to 788.

NEL domain constructs: IpaH1.4283 to 575, IpaH9.8252 to 545, SspH1 405 to 700, SspH2 493 to 788.

Substrate ubiquitination assays

NEL E3 ligase constructs of IpaH1.4, IpaH9.,8 and SspH1 (1 μM) were incubated at 22 °C with shaking with their respective substrates LUBAC (C82A, 1 μM), GBP1 (1 μM), and PKN1 (residues 122–199, 2 μM) in the presence of 0.1 μM E1, 2 μM UbcH5A, 20 μM Ub, and 10 mM ATP in 25 mM Hepes (pH 7.5), 150 mM NaCl, 10 mM MgCl2 for 0 to 30 min. Samples were quenched with LDS loading dye containing DTT, separated by SDS-PAGE on 4 to 12% gels, and stained with Coomassie.

Autoubiquitination assays

NEL E3 ligase constructs of IpaH1.4, IpaH9.8, SspH1, and SspH2 (1 μM) were incubated at 22 °C with shaking in the presence of 0.1 μM E1, 2 μM UbcH5A, 20 μM Ub, and 10 mM ATP in 25 mM Hepes (pH 7.5), 150 mM NaCl, and 10 mM MgCl2 for 0 to 30 min. Samples were quenched with LDS loading dye containing DTT, separated by SDS-PAGE on 4 to 12% gels, and stained with Coomassie.

Discharge assays

NEL E3 ligase constructs of IpaH1.4, IpaH9.8, SspH1, and SspH2 (100 nM) were incubated at 22 °C with shaking in the presence of 1 μM precharged UbcH5A-Ub-cy3 for 0 to 20 min. Samples were quenched with LDS loading dye, separated by SDS-PAGE on 4 to 12% gels, and scanned on a LI-COR CLx scanner.

UbVS loading assays

NEL E3 ligase constructs of IpaH1.4, IpaH9.8, SspH1, and SspH2 (5 μM) were incubated with 20 μM UbVS (U-202B-050; BioTechne) at 22 °C with shaking for 0 to 120 min. Samples were quenched with LDS loading dye containing DTT, separated by SDS-PAGE on 4 to 12% gels, and stained with Coomassie.

Crystallization, data collection, phasing, and refinement

ΔNSspH1 (161–700) at a concentration of 12 mg/ml was crystallized in 50 mM Hepes (pH 7.5), 150 mM NaCl, and 0.5 mM TCEP at 20 °C. Crystals grew from a sitting drop made of 0.1 μl of protein solution mixed with 0.1 μl of 0.225 M sodium tartrate, 22% PEG 3350, and 11 mM sarcosine. The crystals were cryoprotected with 0.225 M sodium tartrate, 35% PEG 3350, 10% glycerol, and data were collected at Diamond Light Source at the i24 beamline. Data processing was done using DIALS and merged and scaled using AIMLESS (39, 40). The initial model was obtained by molecular replacement using the available coordinates of the SspH1 LRR domain (4NKH) and the coordinates of the NEL domain from the SspH1 AF model as templates in Phenix Phaser (41). Models were iteratively improved by manual building in Coot and refined using both REFMAC and Phenix (41, 42, 43). Coordinates and structure factors are deposited in the PDB with the code 9H6W, and the final refinement statistics are reported in Table S1.

SAXS and SspH1 ensemble modeling

SAXS data were collected at the SWING beamline at SOLEIL. Samples of ΔNSspH1 and FL SspH1 at concentrations 168 μM and 104 μM in 50 mM Hepes (pH 7.5), 150 mM NaCl, and 0.5 mM TCEP in the absence and presence of 1:2 M equivalents of PKN1 were injected onto a Bio SEC-3100 Å Agilent column and eluted at a flow rate of 0.3 ml/min at 15 °C (Fig. S8C). Frames were collected continuously during the fractionation of the proteins (1 frame/s). Frames collected before the void volume (0.6–1.5 ml) were averaged and subtracted from the signal of the elution profile to account for background scattering. Data reduction, subtraction, and averaging were performed using the software FOXTROT (SOLEIL). The scattering curves were analyzed using the package ATSAS (44) and reported as function of the angular momentum transfer q = 4π/λ sinθ, where 2θ is the scattering angle and λ is the wavelength of the incident beam. Values of the cross-sectional radius of gyration were obtained with SCATTER (45).

To model the dynamic behavior of SspH1 and explore its conformational space, we employed an Xplor-NIH protocol (46). Initially, the E2–UbBD (residues 623–697) and the LRR (residues 161–393) domains were randomly oriented relative to a fixed E3 domain (residues 405–622) by randomizing linker torsion angles (note: the LRR–E3 linker has a high B-factor). Subsequently, a high-temperature torsion-angle dynamic at 3000 K was followed by simulated annealing from 3000 K to 25 K in 12.5 K increments. The final step involved gradient minimization in torsion-angle space to generate the structure ensembles. Our calculations incorporated the experimental SAXS-derived force field, knowledge-based energy terms, such as torsion angle potential from conformational databases, and standard Xplor-NIH covalent and nonbonded energy terms. Each ensemble member was assigned a weight corresponding to 1/n, where n is the number of structures in the ensemble. Fifty equidistant points were used to simulate the scattering curve in a q interval of 0 to 0.3.

To avoid overfitting and determine the minimum number of conformers needed to accurately replicate the experimental SAXS data, we initially computed 100 ensembles with one to six conformers each (Fig. S8B). The average χ2 rapidly decreased, plateauing for ensembles with three or more conformations. Subsequently, we calculated 2000 three-conformer ensembles and selected those with χ2 ≤1.5 for analysis (significance level α = 0.05, ensuring statistical significance in the association between the experimental data and our models). Distances between domain centers of mass and intradomain angles were calculated using custom Python scripts. Envelope diameters and radii of gyration for each conformer were evaluated with the program Crysol (same reference of ATSAS).

Nuclear magnetic resonance

NMR experiments were carried out using a Bruker AVANCE spectrometer operating at a proton nominal frequency of 800 MHz. Data were acquired with Topspin (Bruker), processed with NMRPipe (47), and analyzed by CCPNMR (48).

For conjugated Ub NMR, 15N isotope-enriched UbMESNa was expressed and purified in M9 minimal medium using 1 g/l of 15N-ammonium chloride as a sole source of nitrogen. 15N UbMESNa was further reacted with glycine vinyl sulfone (EN300-1264982; Enamine) as described previously (49), to give 15N-UbVS. SspH1 constructs (10 μM) were reacted with 50 μM 15N UbVS for 2 h before purification by gel filtration into 50 mM Hepes (pH 7.5), 75 mM NaCl, and 10.5 mM TCEP.

For Ub titration NMR experiments, 15N isotope-e1nriched Ub was prepared by growing the bacteria1 in M9 minimal medium using 1 g/l 1of 15N-ammonium chloride as a sole source of nitrogen. 15N-Ub was titrated with SspH1 constructs, and measurements were taken as described previously. Chemical shift changes for the backbone amide proton and nitrogen nuclei (ΔδNH) were calculated according to a procedure implemented in CCPNMR analysis (48).

Data availability

Coordinates and structure factors are deposited in the PDB with accession code 9H6W. All other data are contained within the article and supporting information.

Supporting information

This article contains supporting information.

Conflict of interest

The authors declare that they have no conflicts of interest with the contents of this article.

Acknowledgments

We thank Andrew Purkiss for crystallography data collection, Aurelien Thureau for SAXS beamline support, and Ian Taylor for help with SEC–MALLS experiments. X-ray crystallography data collection was performed on the i24 beamline at Diamond and SAXS data collection on the SWING beamline at Soleil synchrotrons. For the purpose of open access, the author has applied a CC BY public copyright license to any author-accepted manuscript version arising from this submission. Figures were created in BioRender.com under the institutional license belonging to the Francis Crick Institute.

Author contributions

D. H. and K. R. conceptualization; C. R. K. and D. E. formal analysis; C. R. K., D. E., and J. H. investigation; C. R. K. and D. E. data curation; C. R. K. and D. E. writing–original draft; C. R. K., D. E., D. H., and K. R. writing–review & editing; C. R. K., D. E., and J. H. visualization; D. H. and K. R. supervision; D. H. and K. R. project administration; D. H. and K. R. funding acquisition.

Funding and additional information

This work was supported by the Francis Crick Institute, which receives its core funding from Cancer Research United Kingdom (CC 2075), the United Kingdom Medical Research Council (CC 2075), and the Wellcome Trust (CC 2075); by the Biotechnology and Biological Research Council, BB/T014547/1 (to K. R. and D. H.); and by the Engineering and Physical Sciences Research Council, EP/V038028/1 (to D. H. and K. R.).

Reviewed by members of the JBC Editorial Board. Edited by Joseph Jez

Supporting information

Supplementary Material
mmc1.pdf (8.9MB, pdf)

References

  • 1.Nemhauser J. OUP USA; Atlanta, GA: 2023. Travel-associated infections & diseases. CDC Yellow Book 2024; pp. 243–548. [Google Scholar]
  • 2.Pillay T.D., Hettiarachchi S.U., Gan J., Diaz-Del-Olmo I., Yu X.J., Muench J.H., et al. Speaking the host language: how salmonella effector proteins manipulate the host. Microbiology. 2023;169 doi: 10.1099/mic.0.001342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Nasser A., Mosadegh M., Azimi T., Shariati A. Molecular mechanisms of Shigella effector proteins: a common pathogen among diarrheic pediatric population. Mol. Cell. Pediatr. 2022;9:1–21. doi: 10.1186/s40348-022-00145-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Komander D., Rape M. The ubiquitin code. Annu. Rev. Biochem. 2012;81:203–229. doi: 10.1146/annurev-biochem-060310-170328. [DOI] [PubMed] [Google Scholar]
  • 5.Berglund J., Gjondrekaj R., Verney E., Maupin-Furlow J.A., Edelmann M.J. Modification of the host ubiquitome by bacterial enzymes. Microbiol. Res. 2020;235 doi: 10.1016/j.micres.2020.126429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Roberts C.G., Franklin T.G., Pruneda J.N. Ubiquitin-targeted bacterial effectors: rule breakers of the ubiquitin system. EMBO J. 2023;42 doi: 10.15252/embj.2023114318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Maculins T., Fiskin E., Bhogaraju S., Dikic I. Bacteria-host relationship: ubiquitin ligases as weapons of invasion. Cell. Res. 2016;26:499–510. doi: 10.1038/cr.2016.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Singer A.U., Rohde J.R., Lam R., Skarina T., Kagan O., Dileo R., et al. Structure of the Shigella T3SS effector IpaH defines a new class of E3 ubiquitin ligases. Nat. Struct. Mol. Biol. 2008;15:1293–1301. doi: 10.1038/nsmb.1511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Zhu Y., Li H., Hu L., Wang J., Zhou Y., Pang Z., et al. Structure of a Shigella effector reveals a new class of ubiquitin ligases. Nat. Struct. Mol. Biol. 2008;15:1302–1308. doi: 10.1038/nsmb.1517. [DOI] [PubMed] [Google Scholar]
  • 10.Bernal-Bayard A., Bernal-Bayard J., Ramos-Morales F. The NEL family of bacterial E3 ubiquitin ligases. Int. J. Mol. Sci. 2022;23:7725. doi: 10.3390/ijms23147725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Cook M., Delbecq S.P., Schweppe T.P., Guttman M., Klevit R.E., Brzovic P.S. The ubiquitin ligase SspH1 from Salmonella uses a modular and dynamic E3 domain to catalyze substrate ubiquitylation. J. Biol. Chem. 2019;294:783–793. doi: 10.1074/jbc.RA118.004247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Piro A.S., Hernandez D., Luoma S., Feeley E.M., Finethy R., Yirga A., et al. Detection of cytosolic Shigella flexneri via a C-terminal triple-arginine motif of GBP1 inhibits actin-based motility. mBio. 2017;8 doi: 10.1128/mBio.01979-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Wandel M.P., Pathe C., Werner E.I., Ellison C.J., Boyle K.B., von der Malsburg A., et al. GBPs inhibit motility of Shigella flexneri but are targeted for degradation by the bacterial ubiquitin ligase IpaH9.8. Cell. Host. Microbe. 2017;22:507–518.e5. doi: 10.1016/j.chom.2017.09.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Li P., Jiang W., Yu Q., Liu W., Zhou P., Li J., et al. Ubiquitination and degradation of GBPs by a Shigella effector to suppress host defence. Nature. 2017;551:378–383. doi: 10.1038/nature24467. [DOI] [PubMed] [Google Scholar]
  • 15.Rohde J.R., Breitkreutz A., Chenal A., Sansonetti P.J., Parsot C. Type III secretion effectors of the IpaH family are E3 ubiquitin ligases. Cell. Host. Microbe. 2007;1:77–83. doi: 10.1016/j.chom.2007.02.002. [DOI] [PubMed] [Google Scholar]
  • 16.Ashida H., Kim M., Schmidt-Supprian M., Ma A., Ogawa M., Sasakawa C. A bacterial E3 ubiquitin ligase IpaH9.8 targets NEMO/IKKγ to dampen the host NF-κB-mediated inflammatory response. Nat. Cell. Biol. 2009;12:66–73. doi: 10.1038/ncb2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.De Jong M.F., Liu Z., Chen D., Alto N.M. Shigella flexneri suppresses NF-κB activation by inhibiting linear ubiquitin chain ligation. Nat. Microbiol. 2016;1:1–11. doi: 10.1038/nmicrobiol.2016.84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Hansen J.M., de Jong M.F., Wu Q., Zhang L.S., Heisler D.B., Alto L.T., et al. Pathogenic ubiquitination of GSDMB inhibits NK cell bactericidal functions. Cell. 2021;184:3178–3191.e18. doi: 10.1016/j.cell.2021.04.036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Haraga A., Miller S.I. A Salmonella enterica serovar typhimurium translocated leucine-rich repeat effector protein inhibits NF-κB-dependent gene expression. Infect. Immun. 2003;71:4052–4058. doi: 10.1128/IAI.71.7.4052-4058.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Haraga A., Miller S.I. A Salmonella type III secretion effector interacts with the mammalian serine/threonine protein kinase PKN1. Cell. Microbiol. 2006;8:837–846. doi: 10.1111/j.1462-5822.2005.00670.x. [DOI] [PubMed] [Google Scholar]
  • 21.Bhavsar A.P., Brown N.F., Stoepel J., Wiermer M., Martin D.D.O., Hsu K.J., et al. The Salmonella type III effector SspH2 specifically exploits the NLR Co-chaperone activity of SGT1 to subvert immunity. PLoS. Pathog. 2013;9 doi: 10.1371/journal.ppat.1003518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Bernal-Bayard J., Ramos-Morales F. Salmonella type III secretion effector SlrP is an E3 ubiquitin ligase for mammalian thioredoxin. J. Biol. Chem. 2009;284:27587–27595. doi: 10.1074/jbc.M109.010363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Rahighi S., Ikeda F., Kawasaki M., Akutsu M., Suzuki N., Kato R., et al. Specific recognition of linear ubiquitin chains by NEMO is important for NF-κB activation. Cell. 2009;136:1098–1109. doi: 10.1016/j.cell.2009.03.007. [DOI] [PubMed] [Google Scholar]
  • 24.Xia Z.P., Sun L., Chen X., Pineda G., Jiang X., Adhikari A., et al. Direct activation of protein kinases by unanchored polyubiquitin chains. Nature. 2009;461:114–119. doi: 10.1038/nature08247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Skaug B., Chen J., Du F., He J., Ma A., Chen Z.J. Direct, noncatalytic mechanism of IKK inhibition by A20. Mol. Cell. 2011;44:559–571. doi: 10.1016/j.molcel.2011.09.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Catici D.A.M., Horne J.E., Cooper G.E., Pudney C.R. Polyubiquitin drives the molecular interactions of the NF-κB essential modulator (NEMO) by allosteric regulation. J. Biol. Chem. 2015;290:14130–14139. doi: 10.1074/jbc.M115.640417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Keszei A.F.A., Tang X., McCormick C., Zeqiraj E., Rohde J.R., Tyers M., et al. Structure of an SspH1-PKN1 complex reveals the basis for host substrate recognition and mechanism of activation for a bacterial E3 ubiquitin ligase. Mol. Cell. Biol. 2014;34:362–373. doi: 10.1128/MCB.01360-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Quezada C.M., Hicks S.W., Galán J.E., Erec Stebbins C. A family of Salmonella virulence factors functions as a distinct class of autoregulated E3 ubiquitin ligases. Proc. Natl. Acad. Sci. U. S. A. 2009;106:4864. doi: 10.1073/pnas.0811058106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Ye Y., Xiong Y., Huang H. Substrate-binding destabilizes the hydrophobic cluster to relieve the autoinhibition of bacterial ubiquitin ligase IpaH9.8. Commun. Biol. 2020;3:1–14. doi: 10.1038/s42003-020-01492-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Keszei A.F.A., Sicheri F. Mechanism of catalysis, E2 recognition,& autoinhibition for the IpaH family of bacterial E3 ubiquitin ligases. Proc. Natl. Acad. Sci. U. S. A. 2017;114:1311–1316. doi: 10.1073/pnas.1611595114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Madeira F., Pearce M., Tivey A.R.N., Basutkar P., Lee J., Edbali O., et al. Search and sequence analysis tools services from EMBL-EBI in 2022. Nucleic. Acids. Res. 2022;50:W276–W279. doi: 10.1093/nar/gkac240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Jumper J., Evans R., Pritzel A., Green T., Figurnov M., Ronneberger O., et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583–589. doi: 10.1038/s41586-021-03819-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Varadi M., Anyango S., Deshpande M., Nair S., Natassia C., Yordanova G., et al. AlphaFold protein structure database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic. Acids. Res. 2022;50:D439–D444. doi: 10.1093/nar/gkab1061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Varadi M., Bertoni D., Magana P., Paramval U., Pidruchna I., Radhakrishnan M., et al. AlphaFold protein structure database in 2024: providing structure coverage for over 214 million protein sequences. Nucleic. Acids. Res. 2024;52:D368–D375. doi: 10.1093/nar/gkad1011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Zouhir S., Bernal-Bayard J., Cordero-Alba M., Cardenal-Muñoz E., Guimaraes B., Lazar N., et al. The structure of the Slrp–Trx1 complex sheds light on the autoinhibition mechanism of the type III secretion system effectors of the NEL family. Biochem. J. 2014;464:135–144. doi: 10.1042/BJ20140587. [DOI] [PubMed] [Google Scholar]
  • 36.Chou Y.C., Keszei A.F.A., Rohde J.R., Tyers M., Sicheri F. Conserved structural mechanisms for autoinhibition in IpaH ubiquitin ligases. J. Biol. Chem. 2012;287:268–275. doi: 10.1074/jbc.M111.316265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Schwieters C.D., Clore G.M. Using small angle solution scattering data in Xplor-NIH structure calculations. Prog. Nucl. Magn. Reson. Spectrosc. 2014;80:1–11. doi: 10.1016/j.pnmrs.2014.03.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Evans R., O’Neill M., Pritzel A., Antropova N., Senior A., Green T., et al. Protein complex prediction with AlphaFold-Multimer. bioRxiv. 2021. 2022;10 [Google Scholar]
  • 39.Winter G., Beilsten-Edmands J., Devenish N., Gerstel M., Gildea R.J., McDonagh D., et al. DIALS as a toolkit. Protein. Sci. 2022;31:232–250. doi: 10.1002/pro.4224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Evans P.R., Murshudov G.N. How good are my data and what is the resolution? Acta Crystallogr. D. Biol. Crystallogr. 2013;69:1204–1214. doi: 10.1107/S0907444913000061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Adams P.D., Afonine P.V., Bunkóczi G., Chen V.B., Davis I.W., Echols N., et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta. Crystallogr. D. Biol. Crystallogr. 2010;66:213–221. doi: 10.1107/S0907444909052925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta. Crystallogr. D. Biol. Crystallogr. 2004;60:2126–2132. doi: 10.1107/S0907444904019158. [DOI] [PubMed] [Google Scholar]
  • 43.Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta. Crystallogr. D. Biol. Crystallogr. 1997;53:240–255. doi: 10.1107/S0907444996012255. [DOI] [PubMed] [Google Scholar]
  • 44.Franke D., Petoukhov M.V., Konarev P.V., Panjkovich A., Tuukkanen A., Mertens H.D.T., et al. Atsas 2.8: a comprehensive data analysis suite for small-angle scattering from macromolecular solutions. J. Appl. Crystallogr. 2017;50:1212–1225. doi: 10.1107/S1600576717007786. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Rambo R.P., Tainer J.A. Characterizing flexible and intrinsically unstructured biological macromolecules by SAS using the porod-debye law. Biopolymers. 2011;95:559–571. doi: 10.1002/bip.21638. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Schwieters C.D., Clore G.M. Using small angle solution scattering data in Xplor-NIH structure calculations. Prog. Nucl. Magn. Reson. Spectrosc. 2014;0:1. doi: 10.1016/j.pnmrs.2014.03.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Delaglio F., Grzesiek S., Vuister G.W., Zhu G., Pfeifer J., Bax A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR. 1995;6:277–293. doi: 10.1007/BF00197809. [DOI] [PubMed] [Google Scholar]
  • 48.Vranken W.F., Boucher W., Stevens T.J., Fogh R.H., Pajon A., Llinas M., et al. The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins. 2005;59:687–696. doi: 10.1002/prot.20449. [DOI] [PubMed] [Google Scholar]
  • 49.Wilkinson K.D., Gan-Erdene T., Kolli N. Derivitization of the c-terminus of ubiquitin and ubiquitin-like proteins using intein chemistry: methods and uses. Methods. Enzymol. 2005;399:37–51. doi: 10.1016/S0076-6879(05)99003-4. [DOI] [PubMed] [Google Scholar]
  • 50.Burger V.M., Arenas D.J., Stultz C.M. A structure-free method for quantifying conformational flexibility in proteins. Sci. Rep. 2016;6:1–9. doi: 10.1038/srep29040. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Material
mmc1.pdf (8.9MB, pdf)

Data Availability Statement

Coordinates and structure factors are deposited in the PDB with accession code 9H6W. All other data are contained within the article and supporting information.


Articles from The Journal of Biological Chemistry are provided here courtesy of American Society for Biochemistry and Molecular Biology

RESOURCES